A Systemic Review of Resistance Mechanisms and Ongoing Clinical Trials in ALK-rearranged Non-Small Cell Lung Cancer

The identification of oncogenic driver driver mutations in non-small cell lung cancer has led to a paradigm shift and the development of specific molecular treatments. Tumors harboring a rearranged EML4-ALK fusion oncogene are highly sensitive to therapy with ALK-targeted inhibitors. Crizotinib is...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Khashayar eEsfahani, Jason Scott Agulnik, Victor eCohen
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Frontiers Media S.A. 2014-07-01
coleção:	Frontiers in Oncology
Assuntos:	Clinical Trials as Topic anaplastic lymphoma kinase (ALK) crizotinib Non small cell lung cancer driver mutations ALK inhibitors
Acesso em linha:	http://journal.frontiersin.org/Journal/10.3389/fonc.2014.00174/full
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!